NCT07071233Completed
Efficacy of Vitamin C Supplementation on Serum TNF-α Levels and Disease Activity in SLE Patients
Efficacy of Vitamin C Supplementation on Serum TNF-α Levels and Disease Activity in Systemic Lupus Erythematosus Patients
Source: ClinicalTrials.gov · Last updated 17 Jul 2025
Brief summary (registry, in English)
The study aimed to evaluate the efficacy of vitamin C supplementation compared to placebo towards TNF-α levels and disease activity with the MEX-SLEDAI score in Systemic Lupus Erythematosus (SLE) patients. The current study was designed as a single-center double-blind randomized controlled clinical trial. The participants were voluntarily recruited ≥ 18 years old SLE patients, with mild to moderate disease activity and did not consumed vitamin C 1 week prior to the trial study. Participants were randomized into two groups receiving vitamin C supplementation, or placebo. TNF-α levels and MEX-SLEDAI score were evaluated at the beginning and at the end of the 8 week trial for analysis.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 38 (actual)
- First submitted
- 30 Jun 2025
- Start date
- 1 Sept 2024
- Primary completion date
- 30 Nov 2024
- Lead sponsor
- Universitas Sriwijaya
- Diseases
- Lupus (SLE)
- NCT number
- NCT07071233
What you commit to
- Study type: Interventional
- Participants enrolled: 38
- From 1 Sept 2024 to the primary completion date, 30 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients currently taking supplements containing vitamin C for more than 1 week.
- Development of serious drug side effects, requiring discontinuation of the medication.
Other illness
- Patients with other immune disorders such as HIV, Rheumatoid Arthritis, Pulmonary Tuberculosis, chronic liver disease, and malignancies.
- Patients with a diagnosis of SLE with severe disease activity or those who have reached remission.
- Patients with comorbid conditions such as hemochromatosis and gastritis.
- Drop-out Criteria
Other
- Pregnant or breastfeeding.
- Patients who are hospitalized due to SLE.
- Patients who discontinue vitamin C for more than 3 weeks.
- Death.
- Patients who are readmitted or experience symptom deterioration during the intervention period.
- Loss to follow-up.
Who the study is looking for
- All patients diagnosed with systemic lupus erythematosus with mild-moderate disease activity who are treated at the Allergy-Immunology Department of RSMH.
- Patients aged over 18 years.
- Willing to participate in the study by signing an informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mohammad Hoesin General Hospital Coordinator of this site? Confirm its status | Palembang | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.